# A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

> **NCT05593029** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 929 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** SEP-363856
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05593029
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-09
- **Primary completion:** 2025-11-06
- **Final completion:** 2025-11-13
- **Target enrollment:** 929 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593029, "A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05593029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*